Tolerability and Safety of Lacosamide in Neonatal Population

J Child Neurol. 2023 Mar;38(3-4):137-141. doi: 10.1177/08830738231164835. Epub 2023 Mar 27.

Abstract

Lacosamide is a newer antiepileptic medication used in refractory neonatal seizures with limited safety and efficacy data. This case series spans 4 years and includes 38 neonates cared for in the neonatal, pediatric, and cardiovascular intensive care units, who received lacosamide for refractory seizures. Because lacosamide affects atrioventricular node function in adults, among other metrics, electrocardiogram (ECG) changes were monitored closely in these neonates. Within this cohort, 2 neonates were found to have atrial bigeminy on ECG and telemetry. Otherwise, lacosamide was generally well tolerated with sleepiness being the most common symptom noted. This case series reports data on the tolerability of lacosamide and emphasizes the importance of monitoring key cardiac intervals with ECG before and after the use of lacosamide in this population.

Keywords: Antiepileptic drugs; Lacosamide; Neonatal Seizures; Neonate; Seizures‌; Status Epileptius‌.

MeSH terms

  • Acetamides* / adverse effects
  • Adult
  • Anticonvulsants / adverse effects
  • Child
  • Epilepsy* / drug therapy
  • Humans
  • Infant, Newborn
  • Lacosamide / adverse effects
  • Seizures / drug therapy
  • Treatment Outcome

Substances

  • Lacosamide
  • Acetamides
  • Anticonvulsants